
Annual report 2022
added 08-30-2022
Genetic Technologies Limited Market Cap 2011-2025 | GENE
As of December 15, 2025 Genetic Technologies Limited has a market cap of $ 7.1 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.22 B | 17.1 B | 16.6 B | 11.7 M | 19.8 M | 12.9 M | 26 M | 24.4 M | 17.4 M | 40.1 M | 57.6 M | 81.5 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 B | 11.7 M | 3.6 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.36 | -4.05 % | $ 176 M | ||
|
Brainsway Ltd.
BWAY
|
240 M | $ 17.05 | -2.15 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
3.55 M | $ 1.63 | -2.11 % | $ 2.07 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | ||
|
IQVIA Holdings
IQV
|
35.7 B | $ 221.54 | -1.96 % | $ 40.2 B | ||
|
Castle Biosciences
CSTL
|
709 M | $ 38.85 | 2.32 % | $ 1.08 B | ||
|
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | ||
|
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | ||
|
Danaher Corporation
DHR
|
152 B | $ 227.08 | -2.28 % | $ 166 B | ||
|
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | ||
|
DarioHealth Corp.
DRIO
|
43.4 M | $ 11.92 | -6.58 % | $ 338 M | ||
|
DexCom
DXCM
|
48.8 B | $ 66.91 | -2.94 % | $ 25.8 B | ||
|
CareDx, Inc
CDNA
|
521 M | $ 20.44 | 3.23 % | $ 1.1 B | ||
|
Celcuity
CELC
|
399 M | $ 105.26 | 4.46 % | $ 4.15 B | ||
|
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
70.8 K | $ 3.59 | -25.21 % | $ 115 K | ||
|
Exact Sciences Corporation
EXAS
|
9.32 B | $ 101.58 | 0.21 % | $ 18.8 B | ||
|
Co-Diagnostics
CODX
|
34.9 M | $ 0.34 | -2.96 % | $ 9.98 M | ||
|
Fulgent Genetics
FLGT
|
467 M | $ 27.13 | 0.26 % | $ 820 M | ||
|
Guardant Health
GH
|
5.84 B | $ 102.09 | 0.7 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | ||
|
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 26.6 | -1.52 % | $ 20 B | ||
|
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
16.4 B | $ 134.29 | -1.58 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
8.54 B | $ 192.57 | -0.96 % | $ 9.89 B | ||
|
Quidel Corporation
QDEL
|
10.6 B | $ 28.79 | -2.93 % | $ 1.21 B | ||
|
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
19.1 B | $ 182.21 | 0.35 % | $ 20.2 B | ||
|
Biodesix
BDSX
|
92.1 M | $ 7.94 | -1.0 % | $ 1.03 B | ||
|
Laboratory Corporation of America Holdings
LH
|
21.1 B | $ 263.51 | -0.46 % | $ 22.1 B | ||
|
ICON Public Limited Company
ICLR
|
16.6 B | $ 186.28 | -1.92 % | $ 15.4 B | ||
|
IDEXX Laboratories
IDXX
|
37.7 B | $ 701.07 | -0.91 % | $ 57.8 B | ||
|
Lantheus Holdings
LNTH
|
6.47 B | $ 66.11 | 4.76 % | $ 4.57 B | ||
|
Agilent Technologies
A
|
42 B | $ 139.44 | -2.4 % | $ 42.4 B | ||
|
Biomerica
BMRA
|
7.19 M | $ 2.55 | -1.07 % | $ 5.86 M | ||
|
Bioventus
BVS
|
351 M | $ 7.59 | 2.29 % | $ 475 M | ||
|
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | ||
|
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
29.9 B | $ 1 395.23 | -1.85 % | $ 29.6 B | ||
|
Myriad Genetics
MYGN
|
973 M | $ 7.26 | -0.62 % | $ 658 M | ||
|
ENDRA Life Sciences
NDRA
|
2.2 M | $ 5.47 | -7.6 % | $ 2.94 M |